Skip to content
Study details
Enrolling now

Spironolactone Trial to Improve Pregnancy-Associated Hypertension

Massachusetts General Hospital
NCT IDNCT07041281ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

204

Study length

about 3.4 years

Ages

18+

Sex

Female only

Locations

3 sites in MA, PA

About this study

Researchers are testing whether spironolactone, a medication that blocks the mineralocorticoid receptor, can improve blood pressure and heart health in women who have had gestational hypertension or preeclampsia. The trial will last for 1233 days (about three years) after delivery.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Placebo tablet to match spironolactone
  • 2.Take spironolactone 25 mg orally once daily
PhasePhase 2
Drugspironolactone 25 mg orally once daily
Routeoral
Primary goalMean 24-hour ambulatory diastolic blood pressure

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low14%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

diuretic (Potassium-sparing diuretic; aldosterone antagonist)

Drug routes

oral (Oral Tablet), oral

Endpoints

Primary: Mean 24-hour ambulatory diastolic blood pressure

Secondary: Mean 24-hour ambulatory systolic blood pressure, Mean diurnal ambulatory diastolic blood pressure, Mean diurnal ambulatory systolic blood pressure, Mean nocturnal ambulatory diastolic blood pressure, Mean nocturnal ambulatory systolic blood pressure, Measured diastolic blood pressure, Measured systolic blood pressure, N-terminal pro-B-type natriuretic peptide

Body systems

Reproductive Health, Cardiology / Heart